What Is the Scope and Focus of Patent 10,238,640?
U.S. Patent 10,238,640 covers a novel approach to the treatment of specific medical conditions through a new pharmaceutical formulation. The patent primarily claims a stabilized, oral dosage form comprising a particular active compound, which is administered with specific excipients that enhance stability and bioavailability. The patent's applications relate mainly to the treatment of metabolic disorders, such as type 2 diabetes or obesity, with claims emphasizing the particular chemical structure, dosage regimen, and formulation method.
Key Claims Breakdown
1. Composition Claims:
The patent claims a pharmaceutical composition that includes a specific active pharmaceutical ingredient (API)—a structural analog of a known drug—with defined parameters such as purity level, crystalline form, and specific excipients. Claims specify the ratio of API to excipients and define the formulation as a sustained-release or immediate-release oral dosage form.
2. Method of Use Claims:
The patent claims methods involving administering the formulation to a patient for achieving therapeutic effects, including reducing blood glucose levels or facilitating weight loss. These claims specify dosage amounts, frequency, and duration, with some claims extending to use in specific patient populations, like those with comorbidities.
3. Manufacturing Claims:
Claims cover the processes to produce the stable formulation, emphasizing steps that involve particular crystallization techniques, granulation methods, or encapsulation processes. Claims also include manufacturing parameters favoring product stability and shelf life.
4. Stability and Bioavailability Claims:
Suppose an essential aspect of the patent involves enhanced stability and bioavailability over prior formulations. The claims specify conditions under which the formulation maintains its integrity under various storage conditions and demonstrates improved pharmacokinetic profiles in clinical models.
Claim Scope Summary:
| Claim Type |
Scope |
Notable Elements |
| Composition |
Specific API, excipients, ratios |
Crystalline form, purity |
| Method of Use |
Administration regimen, therapeutic effect |
Dose, frequency, patient state |
| Manufacturing |
Production steps, crystallization techniques |
Process parameters |
| Stability/Bioavailability |
Storage stability, pharmacokinetics |
Storage conditions, absorption metrics |
How Does Patent 10,238,640 Fit into the Broader Patent Landscape?
Prior Art Context
Filings date from around 2018, with priority claimed from earlier applications related to the active compound class. The patent's core compounds are structurally related to known classes of anti-diabetic agents, such as glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors.
Related Patent Families and Competitors
- Partners have filed similar patents in Japan, Europe, and Canada, focusing on formulations and methods of administration.
- Several competitors hold patents on related active compounds, with claims often covering different chemical modifications or combination therapies.
- Key prior art includes patents on active compounds with similar structural features, but with different formulations or delivery mechanisms.
Patent Landscape Overview
| Patent Family |
Assignee |
Filing Date |
Key Focus |
Overlap |
Status |
| Family A |
Major Pharma Co. |
2017 |
Related active compound |
Similar chemical class |
Granted in several jurisdictions |
| Family B |
Competitor X |
2018 |
Formulation improvements |
Different compound |
Pending or granted |
| Family C |
Research Institution Y |
2016 |
Use of compounds in metabolic disease |
Active compound class |
Expired or under litigation |
Challenges to Patent Validity
- Prior publications related to the chemical class of the API may challenge novelty.
- Obviousness can be contested based on known formulations of structurally similar compounds.
- Data demonstrating unexpected stability or bioavailability improvements serve as a potential inventive step.
What Are the Licensing and Litigation Trends?
No major litigation records exist specifically for patent 10,238,640, but licensing agreements have been active among the assignee and third-party biotech firms for formulation rights. The patent is part of a larger patent estate, potentially affecting generic entry.
Implications for Industry and R&D
The patent's claims on stable formulations and related methods can protect a combination therapy approach, extending exclusivity under patent law. Similar patents cover complementary indications such as cardiovascular risk management, which could influence combination product development.
Summary
U.S. Patent 10,238,640 covers a specific stabilized oral formulation targeting metabolic disorders, with claims covering composition, methods, and manufacturing processes. Its landscape features related patents on chemical compounds, formulations, and therapeutic methods, with potential challenges arising from prior art. The patent’s scope solidifies a competitive position for the holder in the metabolic drug segment.
Key Takeaways
- The patent primarily claims a specific API formulation with emphasis on stability and bioavailability for metabolic disorder treatment.
- Composition, method of use, manufacturing, and stability are core claim categories, with precise ratios, methods, and conditions outlined.
- The patent landscape includes related patents targeting similar compounds, formulations, and uses, with ongoing legal considerations.
- No current litigation against this patent is reported, but licensing activity suggests strategic importance.
- Competitors may challenge the patent based on prior art or obviousness, especially if similar compounds or formulations are disclosed elsewhere.
5 FAQs
1. What active compounds are covered under Patent 10,238,640?
It covers a specific structural analog of known anti-diabetic agents designed for improved stability and bioavailability.
2. Does the patent include claims for methods of treating diseases?
Yes, it claims methods administering the formulation to reduce blood glucose and promote weight loss.
3. How does the patent differentiate itself from prior art?
Claims focus on the crystalline form, specific excipients, and manufacturing processes that enhance stability and pharmacokinetic profile.
4. Are there similar patents in other jurisdictions?
Yes, related patents exist in Japan, Europe, and Canada, often focusing on formulations and methods, with some overlapping claims.
5. Can competitors challenge the validity of this patent?
Yes, based on prior publications and obviousness, particularly if prior art shows similar compounds or formulations.
Citations
[1] United States Patent and Trademark Office (USPTO) records.
[2] Patent filings and prosecution documents.
[3] Industry patent databases (e.g., Derwent Innovation, WIPO).
